Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$32.76 - $39.56 $36,429 - $43,990
1,112 Added 8.12%
14,812 $518,000
Q4 2023

Feb 14, 2024

BUY
$14.5 - $38.0 $14,297 - $37,468
986 Added 7.76%
13,700 $521,000
Q3 2023

Nov 14, 2023

BUY
$15.75 - $26.31 $11,072 - $18,495
703 Added 5.85%
12,714 $234,000
Q2 2023

Aug 14, 2023

BUY
$16.96 - $27.82 $203,706 - $334,146
12,011 New
12,011 $312,000

Others Institutions Holding INBX

About Inhibrx, Inc.


  • Ticker INBX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,057,700
  • Market Cap $617M
  • Description
  • Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...
More about INBX
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.